题名 | Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials. | 链接 | https://www.ncbi.nlm.nih.gov/pubmed/?term=30664844 |
https://www.ncbi.nlm.nih.gov/pubmed/?term=30664844 |